Skip to contentpdufa.bio

Ebribafusp alfa

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

Ebribafusp alfa is an Akebia Therapeutics, Inc. program in C3 glomerulopathy, lupus nephritis or IgA nephropathy (basket). Its next catalyst is a Readout in Q4 2027.

AKBA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: C3 glomerulopathy, lupus nephritis or IgA nephropathy (basket). Sponsor: Akebia Therapeutics, Inc. (AKBA). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027AKBA

Questions

When is Ebribafusp alfa's next FDA decision or readout?

The next tracked catalyst for Ebribafusp alfa is a Readout in Q4 2027.

What happened at Ebribafusp alfa's most recent FDA decision?

No FDA decision for Ebribafusp alfa is in our archive yet.

What is Ebribafusp alfa used for?

In our records Ebribafusp alfa is under review or in development for C3 glomerulopathy, lupus nephritis or IgA nephropathy (basket).

Who makes Ebribafusp alfa?

Akebia Therapeutics, Inc. (AKBA).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.